MedTrace Logo

NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions

NCT01870427 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2016-12-08

No results posted yet for this study

Summary

The purpose of the study is to determine the effect of Intravitreal Aflibercept Injection (IAI) on previously treated Central Retinal Vein Occlusions (CRVOs) with other Anti-VEGF agents.

Conditions

  • Macular Edema With Central Retinal Vein Occlusions

Interventions

DRUG

Aflibercept (2.0 mg)

Intravitreal Aflibercept (2.0 mg)

Sponsors & Collaborators

Principal Investigators

  • Rahul N Khurana, MD · Northern California Retina Vitreous Associates

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2015-08-31
Completion
2016-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01870427 on ClinicalTrials.gov